Vaccines R&D & Vaccination

Sen O.M. has education of doctor of veterinary medicine. Holds the position of head of the bacterial and autogenic vaccines sector of the department of development of immunobiological drugs in BIOTESTLAB Ltd. Sen O.M. published 6 articles in professional journals.

According to the report of the European Food Safety Authority (EFSA) on food toxicoinfection, salmonella and campylobacteriosis are the most common. In Ukraine, salmonella is most often caused by two serovars of salmonella - S. enteritidis and S. typhimurium, the specific gravity of which is 94.2% to the total amount of isolated salmonella isolates from humans, animals and birds. Relatively often, salmonellosis is caused by S. gallinarum and S. pulorum. \r\nTherefore, the control of salmonellosis epizootic processes by immunization of breeding flocks of chickens is crucial for prevention of food toxicoinfections of salmonella origin.\r\nTo develop the vaccine against chicken salmonellosis, were selected salmonella strains, that often cause food toxicoinfection, which are S. enteritidis, and S. typhimurium. Also comprehensive studies indicate an increase in the role of S. gallinarum - pulorum as an etiological factor of salmonellosis.\r\nDeveloped by BIOTESTLAB Ltd., vaccine POLIMUN SALMO containing antigens of inactivated with formaldehyde and concentrated cultures of the abovementioned strains of salmonella with the concentration ≥108 CFU/dose.\r\n

Mohammad Hossein Yazdi got his PhD in the field of Pharmaceutical Biotechnology by 2014 from Tehran University of Medical Sciences, School of Pharmacy. His PhD work was about cancer vaccine and immunotherapy. He is now working as Assistant Professor at Biotechnology Research Center and Recombinant Vaccine Research Center of Tehran University of Medical Sciences and pursues his interest in both vaccine and immunotherapy of cancer and infectious diseases. He has published more than 35 papers in reputed journals and has been serving as senior lecturer of advanced immunology and immunotherapy at Tehran University of Medical Sciences.

Induction of cellular immune response in tumor bearing mice and decrease of suppressor factors may result in controlling and inhibition of tumor progression. In the present study, the role of BCG as an immune-adjuvant element in vaccine formulation has been investigated, after immunization with HPV17E7d vaccine using BCG bacteria as adjuvant in tumor bearing mice, the balance of inflammatory and anti-inflammatory cytokines was assessed.\r\n \r\nTumor was established in C57BL/6 mice with transplantation method. Experimental C57BL/6 tumor bearing mice were vaccinated three times with 10 days intervals with E7d protein formulated in Alum and BCG vaccine adjuvants. One week after final immunization, serum samples were obtained from five mice in each group. Then the quantity of IL-4, INF-γ, TNF-α cytokines and total IgG Antibody were evaluated with commercial ELISA kits. Also, the level of IgG1 and IgG2a were measured. In addition, survival and volume of tumors were monitored during the study period. \r\n\r\nResults showed that immunization with vaccine formulated in BCG as adjuvant increased INF-γ and its ratio to IL-4 besides IgG2a as an important antibody. Also, TNF-α and total Antibody level were significantly higher when compared to PBS control and E7d Alum vaccine groups. In addition, survival of vaccinated mice with BCG adjuvant showed longer lifespan and the tumor volume of mice in this group were significantely lower than others.\r\n\r\nRegarding to the present data it can be concluded that formulation of E7d vaccine in BCG Alum can shift the immune responses toward Th1 pattern and cause a better outcome in terms of tumor progress and survival rate. Further studies in this filed will warrant more benefits of this formulation. \r\n